Video:
Atlas Reactor is a game that has a lot of interesting ideas, but a very small amount of press from what I've seen so far. Far less than it deserves. It's been described as DotA meets XCOM and I think that's a pretty apt description. A different spin on Frozen Synapse would be another good description if you played that game.
Gameplay wise, it takes the core MOBA hero concept and brings it into a synchronous turn based death match environment. The gist of it is each turn you and your allies have 20 seconds to plan out your movement & actions of the next turn and then those actions and the actions of your enemy play out in 4 phases (prep, dash, blast, move) simultaneously.
Because of the 20s time limit the game doesn't get bogged down at a slow pace like many other turn based games and the game hits a nice mix of giving you plenty of options while keeping those options discrete enough that the game doesn't feel like there's a big barrier to entry in understanding how to play.
Business Model for the game seems to be evolving over time, but right now the idea is going to be F2P ala League with a Buy-Once option for ranked matches + all heroes. When I last played the beta there was some minor grind to gain a resource that could be used to unlock loadout adjustments (pre-game adjustments to hero abilities that you can equip one per ability) but it felt like a rather brisk pace and easy to get through. Spending money on it given its lack of media attention and potential to not do well is of course a bit of a risk, but you can judge that risk for yourself.
Anyways I enjoyed my time spent in the beta quite a bit, a great thing about the game is the short game length so it's a nice game to play alongside something like DotA where you can play this when you don't want to commit an hour plus to a DotA match.
I'd highly recommend spending a bit of time to check it out at the very least, it does a lot of interesting things that feel new and novel and being f2p you can at least drop in and check out those ideas in practice.